European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) for Six-Week Dosing Schedule Across All Current Monotherapy Indications
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| Merck & Co. (NYSE: MRK) | Delayed: 150.36 +5.69 (3.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $144.67 | 52 Week High | $65.46 | |||
| Open | $148.54 | 52 Week Low | $47.97 | |||
| Day High | $150.42 | P/E | 102.29 | |||
| Day Low | $146.05 | EPS | $1.47 | |||
| Volume | 10,717,259 | |||||
